Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Naive CD4+ at apheresis and disease control at infusion are associated with improved efficacy in second-line CAR T-cells

Blood (2025) 146 (Supplement 1): 2755.

https://doi.org/10.1182/blood-2025-2755

Published: 2025

Journal Articles

Epigenetic reprogramming via EZH1/2 inhibition enhances T cell-mediated immunotherapies against multiple myeloma

Patrizia Porazzi, Martina Pucillo, Anushka Anant Padmanabhan, Siena Nason, Zhixuan Zheng, Luca Paruzzo, Matthew Ho, Peter Michener, Federico Stella, Antonio Imparato, Sandra Susanibar-Adaniya, Alfred Garfall, Joseph Fraietta, Marco Ruella

Blood (2025) 146 (Supplement 1): 2160.

https://doi.org/10.1182/blood-2025-2160

Published: 2025

Journal Articles

CCR5 blockade: A therapeutic approach to uncouple CART-BCMA expansion from CART-mediated immune toxicities.

Blood (2025) 146 (Supplement 1): 5945.

https://doi.org/10.1182/blood-2025-5945

Published: 2025

Journal Articles

Type II interferon-driven crosstalk between effector memory CART and myeloid cells is associated with CART19 resistance in relapsed refractory large B-cell lymphomas

Blood (2025) 146 (Supplement 1): 5337.

https://doi.org/10.1182/blood-2025-5337

Published: 2025

Journal Articles

SMARCA4 deletion enhances CAR T cell cytotoxicity and persistence against cancer

Melody Tan, Josephine Giles, Patrizia Porazzi, Leonel Torres, Luca Paruzzo, Alberto Carturan, Wumesh KC, Yunlin Zhang, Raymone Pajarillo, E. John Wherry, Marco Ruella

Blood (2025) 146 (Supplement 1): 4097.

https://doi.org/10.1182/blood-2025-4097

Published: 2025

Journal Articles

Precision targeting of the malignant clone in B-cell malignancies using chimeric antigen receptor T cells against the clonotypic IGHV3-23 B cell receptor

Jean Lemoine, Ivan Cohen, Gabrielle Croston, Audrey Bochi-Layec, David Espie, Ranjani Ramasubramanian, Patrizia Porazzi, Federico Stella, Pedram Bayat, Seul Jung, Anastasia Iatrou, Andreas Agathangelidis, Stephen Schuster, Paolo Ghia, Kostas Stamatopoulos, Marco Ruella

Blood (2025) 146 (Supplement 1): 2348.

https://doi.org/10.1182/blood-2025-2348

Published: 2025

Journal Articles

A newly identified role for IL-5 in regulating CART-associated toxicity and efficacy

Blood (2025) 146 (Supplement 1): 808.

https://doi.org/10.1182/blood-2025-808

Published: 2025

Journal Articles

Delayed neurotoxicity, enterocolitis, and BCMA-CART-associated immune-related adverse events (CirAE) are caused by CD4+ CAR T-cells

Blood (2025) 146 (Supplement 1): 804.

https://doi.org/10.1182/blood-2025-804

Published: 2025

Journal Articles

Chimeric antigen receptor T-cell therapy in patients with coexisting malignancy and autoimmune disease

Blood (2025) 146 (Supplement 1): 4543.

https://doi.org/10.1182/blood-2025-4543

Published: 2025

Journal Articles

Identification and functional characterization of a novel best-in-class anti-CD79b CAR T cell immunotherapy using a multidimensional screening strategy

Blood (2025) 146 (Supplement 1): 5905.

https://doi.org/10.1182/blood-2025-5905

Published: 2025

Journal Articles

β‑hydroxybutyrate metabolism enhances CAR T cell function via transcriptional and epigenetic reprogramming

Shan Liu, Puneeth Guruprasad, Ranjani Ramasubramanian, Bhoomi Madhu, Luca Paruzzo, Kecheng Han, Alexander Shestov, Chaoting Zhou, Jason Lin, Alberto Carturan, Patrizia Porazzi, Elise Chong, Stephen Schuster, Michael Milone, Christoph Thaiss, Maayan Levy, Marco Ruella

Blood (2025) 146 (Supplement 1): 5903.

https://doi.org/10.1182/blood-2025-5903

Published: 2025

Journal Articles

Precision targeting of pathogenic B cells and autoantibodies in systemic lupus erythematosus using CAR T cells against the IGHV4-34 B cell receptor

Blood (2025) 146 (Supplement 1): 4120.

https://doi.org/10.1182/blood-2025-4120

Published: 2025

Journal Articles

Efficacy and Safety of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor (CAR) T-Cell Therapies in Patients with Autoimmune Disease and Lymphoma or Myeloma

Blood (2024) 144 (Supplement 1): 7243.

https://doi.org/10.1182/blood-2024-206608

Published: 2024

Journal Articles

Overcoming the Lack of CD2:CD58 Costimulation in Chimeric Antigen Receptor T-Cell Immunotherapies

Alberto Carturan, Mathew G. Angelos, Raymone Pajarillo, Jesse Rodriguez, Jaryse Harris, Yunlin Zhang, Ekta Singh, Andrew Lee, Ositadimma Ugwuanyi, Ruchi P. Patel, Puneeth Guruprasad, Jean Lemoine, Jong Hyun Cho, Patrizia Porazzi, Stephen J. Schuster, Marco Ruella

Blood (2024) 144 (Supplement 1): 504.

https://doi.org/10.1182/blood-2024-206061

Published: 2024

Journal Articles

EZH1/2 Inhibition Improves the Anti-Tumor Efficacy of CAR and TCR T-Cell Based Therapies Against Multiple Liquid and Solid Tumors

Siena Nason, Ziqi Yang, Guido Ghilardi, Luca Paruzzo, Alberto Carturan, Eugenio Fardella, Puneeth Guruprasad, Anushka Anant Padmanabhan, Tatiana Blanchard, Gerald Linette, Beatriz M. Carreno, Sandra Susanibar-Adaniya, Alfred L. Garfall, Marco Ruella, Patrizia Porazzi

Blood (2024) 144 (Supplement 1): 4792.

https://doi.org/10.1182/blood-2024-206011

Published: 2024

Journal Articles

CD5-Deleted Chimeric Antigen Receptor Cells (Senza5™ CART5) to Enhance Immunotherapy Against T-Cell Non-Hodgkin Lymphoma: A First-in-Human Phase I Clinical Trial

Blood (2024) 144 (Supplement 1): 7221.

https://doi.org/10.1182/blood-2024-201063

Published: 2024

Journal Articles

Ketogenic Diet Enhances CAR T Cell Antitumor Function Via β-Hydroxybutyrate

Blood (2024) 144 (Supplement 1): 4.

https://doi.org/10.1182/blood-2024-208913

Published: 2024

Journal Articles

Disinhibition of T Cell Activation Via CD5 Knockout Is a Universal Strategy to Enhance Adoptive T Cell Immunotherapies

Ruchi P. Patel, Guido Ghilardi, Yunlin Zhang, Puneeth Guruprasad, Mathew G. Angelos, Raymone Pajarillo, Khatuna Gabunia, Chong Xu, Tatiana Blanchard, John Scholler, Patrizia Porazzi, Gerald Linette, Beatriz M. Carreno, Marco Ruella

Blood (2023) 142 (Supplement 1): 102.

https://doi.org/10.1182/blood-2023-186611

Published: 2023

Journal Articles

Inhibition of EZH2 Improves CART19 Immunotherapy By Reprogramming Lymphoma Tumor Cells and Enhancing T-Cell Functionality

Patrizia Porazzi, Yusuke Isshiki, Guido Ghilardi, Siena Nason, Ziqi Yang, Alberto Carturan, Linhui Chen, Yunlin Zhang, Ruchi P. Patel, Puneeth Guruprasad, Ositadimma Ugwuanyi, Ivan J Cohen, Stephen J Schuster, Ari M Melnick, Wendy BÃ©guelin, Marco Ruella

Blood (2023) 142 (Supplement 1): 1018.

https://doi.org/10.1182/blood-2023-182440

Published: 2023

Journal Articles

EZH2 Inhibitors Enhance CART Cell Quality, Efficacy, In Vivo Homing, Tumor Cell Binding and Killing of Fully Syngeneic Primary B Cell Lymphomas, As Well As Reprogramming Lymphoma Cells to a Highly Immunogenic and T Cell Adherent Phenotype

Yusuke Isshiki, Patrizia Porazzi, Xi Chen, Matthew Teater, Ioannis Karagiannidis, Henna S. Nam, Ari M Melnick, Marco Ruella, Wendy BÃ©guelin

Blood (2023) 142 (Supplement 1): 432.

https://doi.org/10.1182/blood-2023-190610

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Naive CD4+ at apheresis and disease control at infusion are associated with improved efficacy in second-line CAR T-cells

Epigenetic reprogramming via EZH1/2 inhibition enhances T cell-mediated immunotherapies against multiple myeloma

CCR5 blockade: A therapeutic approach to uncouple CART-BCMA expansion from CART-mediated immune toxicities.

Type II interferon-driven crosstalk between effector memory CART and myeloid cells is associated with CART19 resistance in relapsed refractory large B-cell lymphomas

SMARCA4 deletion enhances CAR T cell cytotoxicity and persistence against cancer

Precision targeting of the malignant clone in B-cell malignancies using chimeric antigen receptor T cells against the clonotypic IGHV3-23 B cell receptor

A newly identified role for IL-5 in regulating CART-associated toxicity and efficacy

Delayed neurotoxicity, enterocolitis, and BCMA-CART-associated immune-related adverse events (CirAE) are caused by CD4+ CAR T-cells

Chimeric antigen receptor T-cell therapy in patients with coexisting malignancy and autoimmune disease

Identification and functional characterization of a novel best-in-class anti-CD79b CAR T cell immunotherapy using a multidimensional screening strategy

β‑hydroxybutyrate metabolism enhances CAR T cell function via transcriptional and epigenetic reprogramming

Precision targeting of pathogenic B cells and autoantibodies in systemic lupus erythematosus using CAR T cells against the IGHV4-34 B cell receptor

Efficacy and Safety of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor (CAR) T-Cell Therapies in Patients with Autoimmune Disease and Lymphoma or Myeloma

Overcoming the Lack of CD2:CD58 Costimulation in Chimeric Antigen Receptor T-Cell Immunotherapies

EZH1/2 Inhibition Improves the Anti-Tumor Efficacy of CAR and TCR T-Cell Based Therapies Against Multiple Liquid and Solid Tumors

CD5-Deleted Chimeric Antigen Receptor Cells (Senza5™ CART5) to Enhance Immunotherapy Against T-Cell Non-Hodgkin Lymphoma: A First-in-Human Phase I Clinical Trial

Ketogenic Diet Enhances CAR T Cell Antitumor Function Via β-Hydroxybutyrate

Disinhibition of T Cell Activation Via CD5 Knockout Is a Universal Strategy to Enhance Adoptive T Cell Immunotherapies

Inhibition of EZH2 Improves CART19 Immunotherapy By Reprogramming Lymphoma Tumor Cells and Enhancing T-Cell Functionality

EZH2 Inhibitors Enhance CART Cell Quality, Efficacy, In Vivo Homing, Tumor Cell Binding and Killing of Fully Syngeneic Primary B Cell Lymphomas, As Well As Reprogramming Lymphoma Cells to a Highly Immunogenic and T Cell Adherent Phenotype

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only